Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907269 | 1.00 | NNMT (0.50) | NNMTCYP2A6PIK3CAGABRPGABRD | |
| SCHEMBL957634 | 0.92 | NNMT (0.49) | NNMTCYP2A6PIK3CAGABRPGABRD | |
| SCHEMBL29911687 | 0.83 | NNMT (0.46) | NNMTCYP2A6GABRPGABRDGABRA1 | |
| SCHEMBL14276053 | 0.83 | NNMT (0.46) | NNMTCYP2A6GABRPGABRDGABRA1 | |
| SCHEMBL2614474 | 0.79 | NNMT (0.55) | NNMTCYP2A6PIK3CAGABRPGABRD | |
| SCHEMBL2837318 | 0.79 | GABRA1 (0.41) | NNMTPIK3CAGABRPGABRDGABRA1 | |
| SCHEMBL1459785 | 0.79 | GABRA1 (0.39) | NNMTPIK3CAGABRPGABRDGABRA1 | |
| SCHEMBL1458970 | 0.79 | PIK3CA (0.38) | NNMTPIK3CAMEN1KMT2AHAO1 | |
| SCHEMBL3668216 | 0.78 | UHRF1 (0.56) | NNMTCYP2A6PIK3CAGABRPGABRD | |
| SCHEMBL29492737 | 0.78 | UHRF1 (0.56) | NNMTCYP2A6PIK3CAGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-1799646-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006030032-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-5536745-A | (Hetero)-aryl ketones derivatives with antibacterial properties | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-07-16 | — | — | US | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | NNMT 1301/4885CYP2A6 460/4885PIK3CA 2492/4885 |
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | NNMT 1239/4885CYP2A6 235/4885PIK3CA 1244/4885 |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | NNMT 3399/4885CYP2A6 2845/4885PIK3CA 2026/4885 |
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, ST6GAL1, MGAT1 | NNMT 4717/4885CYP2A6 286/4885PIK3CA 2912/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | NNMT 3399/4885CYP2A6 2845/4885PIK3CA 2026/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | NNMT 609/4885CYP2A6 2664/4885PIK3CA 433/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | NNMT 981/4885CYP2A6 1874/4885PIK3CA 52/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | NNMT 388/4885CYP2A6 2926/4885PIK3CA 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.